The Center for Biosimilars® recaps the top news for the week of April 29, 2019.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 29.
Number 5: The market for orphan drugs is set to grow over the next 4 years, a pharmaceutical report says.
Number 4: Researchers report that patients with psoriasis who switched between 2 different infliximab biosimilars did not have an increase in Psoriasis Area and Severity Index scores or increased adverse events.
Number 3: The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Juta Pharma’s pegfilgrastim biosimilar.
Number 2: Sandoz has entered into a partnership with Taiwan-based EirGenix for a proposed trastuzumab biosimilar referencing Herceptin.
Number 1: Last week, the FDA approved Samsung Bioepis’ etanercept biosimilar referencing Enbrel.
Finally, last week, our e-newsletter asked whether you think that Novartis’ novel eye drug could beat out future biosimilars of aflibercept.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.